Femasys is trading 5.6% up at $4.18 in pre-market action as the stock stages a sharp rebound from recent weakness.
- There is no clear company-specific news, earnings release, or major announcement in available coverage to explain the move.
- The price action points to speculative trading in the low-float biotech name, which is also tracking a modestly risk-on pre-market tone across technology and broader equities.